Immunotherapy plus chemo before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving an immune-boosting drug (Tα1) along with chemotherapy and immunotherapy before surgery helps people with stage II-IIIB non-small cell lung cancer that can be removed. It aims to see if this combination makes the cancer shrink more and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old and have been diagnosed with non-small cell lung cancer that doctors believe can be surgically removed (stages II to IIIB).
- Your tumor does not have EGFR or ALK gene changes, and you have not had any prior treatment for lung cancer like surgery, chemo, or radiation.
- You are in good enough health to have surgery, with a performance status of 0 or 1 (meaning you are fully active or can do light work).
- Your blood counts and organ function (kidney, liver, thyroid, heart) are within certain limits, and you have no active autoimmune disease or uncontrolled infections.
- You are not pregnant, and if you could become pregnant or father a child, you must use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy combined with the immunotherapy drug sintilimab before surgery for people with stage IIA to IIIB non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This study tests a combination of the immunotherapy drug atezolizumab with standard chemotherapy given before surgery for people with stage II to IIIB non-small cell lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy and an immunotherapy drug called sintilimab to shrink unresectable stage IIIB-IIIC non-small cell lung cancer, making it possible to remove it with surgery. The goal is to see if this approach can help patients who aren't candidates for surgery now become candidates later.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.